5-Amino-1MQ vs NAD+

5-Amino-1MQ and NAD+ are two distinct research tools that both target NAD+ metabolism, but at different points in the pathway — making them complementary approaches to the same fundamental biology. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme at the centre of cellular energy production and sirtuin signalling. Direct supplementation with NAD+ elevates the intracellular pool of the coenzyme, supporting the SIRT1–7 enzyme family, PARP-mediated DNA repair, mitochondrial electron transport, and metabolic sensing. Research in this area is substantial: NAD+ depletion has been documented in aged tissues, and restoring NAD+ levels has been shown to improve multiple markers of metabolic health in preclinical models. 5-Amino-1MQ approaches the same endpoint through a different mechanism. Rather than supplying NAD+ directly, it inhibits Nicotinamide N-Methyltransferase (NNMT) — the enzyme that diverts nicotinamide (the primary NAD+ precursor) toward methylation and away from the salvage pathway. By blocking NNMT, 5-Amino-1MQ preserves nicotinamide for NAD+ biosynthesis, effectively increasing endogenous NAD+ production without exogenous supplementation. Researchers studying NAD+ pathway biology frequently position these two compounds as experimental comparators: NAD+ for studies of direct supplementation kinetics and downstream effects, and 5-Amino-1MQ for studies of NNMT-mediated regulation and endogenous pathway rescue. Together they provide a toolkit for dissecting upstream versus downstream NAD+ biology.